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In a recent issue ofCell, King et al. (2013) show that mutations in the ubiquitin ligase subcomponent FBXW7 in-
creaseMYC protein levels and expand the number of leukemia-initiating cells (LICs) in Notch1-induced T-ALL.
Genetic and pharmacological inhibition of MYC abolishes LIC activity with broader therapeutic implications.The leukemogenic activities of cancer-
specific products, such as translocation-
generated fusion proteins or proteins
that are constitutively activated or inacti-
vated by amino acid substitutions, are
in principle easy to understand even if
their ramifications are complicated to
enumerate. Less easy to understand is
how quantitative changes, sometimes
subtle, in the levels of normal proteins
provoke or sustain pathologic activities
during tumorigenesis and progression. A
new study that manipulates Notch1,
FBXW7 (the substrate recognition module
of an E3-ubiquitin ligase complex that
includes both Notch1 and MYC proteins
among its clients), and MYC in mice
reveals how qualitative changes in protein
sequence that inactivate FBXW7 play out
to increase MYC levels in tumor cells that
in turn increase the number of leukemia-
initiating cells (LICs) (Figure 1).
The transmembrane receptor Notch1 is
an important regulator of T cell develop-
ment (Aster et al., 2011). Following recep-
tor binding by one of its ligands, the
intracellular domain of Notch1 is proteo-
lytically processed, released, and traf-
ficked to the nucleus, where it interacts
with DNA-bound Rbpj and helps to recruit
Mastermind-like coactivators to upregu-
late targets involved in metabolism,
proliferation, cell survival, chromatin re-
modeling, and transcription. In T cells
one important downstream effector of
Notch1 action is MYC (Palomero et al.,
2006). In addition to numerous balanced,
nonrandom chromosomal translocations
that occur in T cell acute lymphoblastic
leukemias, 60% of cases have single
nucleotide substitutions or indels that
lead to aberrant Notch1 activation. King
et al. investigate the underlying mecha-
nism for how mutations in Notch1 and8 Cell Stem Cell 13, July 3, 2013 ª2013 ElsevFBXW7 promote leukemia. They find
that stabilization of MYC protein in a
Notch1-activating background increases
the number of LICs, thus showing that
FBXW7 behaves as a tumor suppressor
in T-ALL. The authors show that stabiliza-
tion of MYC by mutation of FBXW7
leads to impaired T cell differentiation, a
dramatically shortened latency period for
leukemogenesis, and the eventual devel-
opment of a more aggressive T-ALL than
that which occurs through the agency of
Notch1 alone. Because removal of the
ubiquitin-targeted destabilizing PEST
sequence in Notch1 did not bypass the
carcinogenic effects of FBXW7 muta-
tions, the authors conclude that FBXW7
operates more upon MYC than Notch1
to increase the LIC population and pro-
voke disease.
The normal MYC protooncogene
may become oncogenic when overex-
pressed. Besides verifying the previously
described transcriptional upregulation of
MYC by activated Notch1, the current
study (King et al., 2013) demonstrates, in
T-ALL with FBXW7 mutations, MYC pro-
tein stabilization due to ineffective
FBXW7-mediated degradation. Although
in principle, high levels ofMYCmight drive
the pathologic expression of nonphysio-
logical targets, more recent studies
indicate that MYC amplifies ongoing
expression within a cell, but does not
directly alter the transcriptional program
of the cell (Lin et al., 2012; Nie et al.,
2012). In other words, MYC is not a spec-
ifier, but an amplifier that controls the flux
of materials and information through sub-
cellular networks. For pathways such as
proliferation and apoptosis, MYC may
push some targets across thresholds
(Shachaf et al., 2008) that discriminate
between bulk leukemia cells and LICs.ier Inc.Crossing these thresholds may not
necessarily be indicative of relentless
and irreversible progression toward
more aggressive disease; rather, it may
reveal the existence of a stochastic
bistable switch in which cells with fluctu-
ating levels of MYC traffic between the
stem-like LIC state and circulating T-lym-
phoblasts. By tagging GFP-MYC knockin
cells using retroviral insertions, the in vivo
fates of individual leukemia clones could
be tracked. Mice transplanted with genet-
ically tagged purified high-MYC LICs
throw off populations of less aggressive,
but similarly tagged, low-MYC cells.
Tracking GFP-MYC in vivo allows the
visualization of heterogeneity in MYC
expression in vivo; such studies demand
that a fully functional MYC fusion protein
be expressed from its endogenous locus
to insure proper regulation and activity
(Nie et al., 2012).
If MYC is an amplifier, then Notch1 is a
specifier and a pioneer factor that en-
gages silent genes to reconfigure their
chromatin and turn them on. During
T cell development, Notch1 also directly
binds and upregulates the otherwise
weakly expressed MYC. The logic of this
interaction is simple: by targeting MYC
expression, Notch1 and other transcrip-
tion factors and signaling pathways
increase their own effectiveness as the
newly synthesized MYC cooperates with
the factor/pathway across the genome.
Using ChIP-Seq, the current work shows
that Notch1 and MYC colocalize at many
if not most sites in T-ALL cells, as
expected from this sort of coherent feed-
forward circuit. The statistically high
stringencies employed in the Chip-Seq
analyses used in this study and many
others rigorously excludes false positive
peaks, but almost certainly considerably
Figure 1. FBXW7 via MYC Amplifies Notch1-Induced Leukemogenesis by Increasing MYC
Protein Levels
Left: activated Notch1 after a latent period yields T-ALL. Leukemia-initiating cells (LICs) require high levels
of MYC (saturated red), but throw off (green arrow) bulk leukemia cells expressing lower levels of MYC
(pale red). Wild-type FBXW7 depresses MYC levels. We speculate that stochastic elevation of MYC
may help promote a bulk leukemia cell to a LIC (pale red arrow). Right: mutated FBXW7 increases
MYC and increases the frequency and numbers of LICs.
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and degree of Notch1-MYC cooperation.
Based on the demonstration that
FBXW7 mutants stabilize MYC, augment-
ing the number and activity of LICs, King
et al. attack the high, oncogenic levels of
MYC by targeting its synthesis at the tran-
scriptional level using the BET-Brd4 inhib-
itor JQ1 and derivatives thereof (Delmore
et al., 2011). MYC transcription is exqui-
sitely Brd4 dependent in some tumors,
especially those of hematopoietic origin
(and most particularly in leukemias and
lymphomas where MYC expression
is driven by translocation-juxtaposed
superhancers) (Loven et al., 2013), yet in
other cancers, especially solid tumors,
BET inhibitors are largely without influ-
ence. Most likely MYC transcription is
driven by different pathways in different
tissues and tumors. In the T-ALL studied
by King et al., MYC, Notch1, and
Brd4 extensively colocalize across the
genome, but especially at enhancers. At
pathologic levels, MYC invades en-
hancers (Loven et al., 2013) and most
likely cooperates with Brd4, Notch1, and
other enhancer-associated activators.
Therefore, attacking MYC via BET inhibi-tors would not only depress MYC syn-
thesis, but likely also reduce the activity
of MYC-associated enhancers by both
decreasing the amount of MYC bound to
the enhancer and preventing Brd4 action
at these same sites.
The systems degrading or stabilizing
MYCmay be cell type dependent accord-
ing to the particular subsets of substrate
specificities for the individual E3-com-
plexes. For example, while FBXW7 coor-
dinates Notch1 and MYC degradation,
other systems may operate elsewhere
and contribute to tissue-specific carcino-
genesis. MULE is an E3-complex associ-
ated with cutaneous tumors (Inoue et al.,
2013).MULE targetsMYC for degradation
in keratinocytes, and to a lesser extent
degrades MIZ1, but has not been re-
ported to target Notch1 (Inoue et al.,
2013). MIZ1 is a zinc-finger protein that
binds to MYC at some of its targets, pre-
venting their activation. In skin, MIZ1 pre-
ventsMYC amplification of CDK inhibitors
(CDKN) p15 and p21, allowing unopposed
proliferation. The utilization of different
E3-specificity modules (i.e., FBXW7
versus MULE) to degrade MYC may pro-
vide its coordinate degradation withCell Stemdifferent partners in different tissues.
Interestingly, activated Notch1 that is pro-
proliferative and carcinogenic in T cells is
a tumor suppressor in skin, suggesting
that uncoupling MYC from Notch1 may
contribute to the definition of their biolog-
ical roles.
Besides context-dependent degrada-
tion, the context-specific utilization of
transcription factors may exploit MYC to
impel developmental (Soufi et al., 2012)
or carcinogenic feedforward amplification
of gene expression as Notch1 does in
T-ALL. For example, androgen receptor
(AR) activates MYC expression and MYC
in turn joins AR at its targets to amplify
hormone response in molecular apocrine
breast cancer. Exposing the pathways
that differentially upregulate or stabilize
MYC in distinct pathologic situations
may highlight targets beyond Brd4 for
pharmacologic intervention. Therefore, it
seems that the very complexity of MYC
synthesis and degradation that con-
founds its simple understanding may
also provide avenues for safer and more
effective tumor-specific therapy.
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